Ehave Looks to Power the Psychedelics Revolution


Ryan Allway

June 30th, 2021

Psychedelics, Top Story


Mental illness will cost the global economy $16 trillion by 2030 due to early-onset and lost productivity, with an estimated 12 billion working days lost due to these conditions each year. 

Conventional therapies have a mixed track record, but psychedelics have shown much promise in recent years. The challenge for researchers and medical professionals is bringing these therapeutics from clinical trials to the clinic where they can drive better patient outcomes.

Let’s see how Ehave Inc. (OTC Pink: EHVVF) aims to supercharge the psychedelic revolution by providing valuable and insightful data and building a mental health ecosystem.

Building a Centralized Platform

Ehave is taking a leading role in developing digital therapeutics by creating an extensible platform to design, build, clinically validate, and deploy robust, condition-specific applications. In addition, the company has partnered with Brain Scientific to access FDA-cleared diagnostic devices and algorithms to populate the platform with data.

For example, the company recently signed an agreement with Silo Wellness Inc. (CSE: SILO) to conduct a brain mapping study on select volunteers at Silo’s Jamaican psilocybin-facilitated wellness retreats. Using Brian Scientific’s NeuroCap and NeuroEEG, Ehave will collect and sort data as Silo administers psilocybin and facilitates the retreat.

Click here to receive an investor presentation and corporate updates

Collecting Data at the Source

Ehave’s consumer-facing platform also makes it easy for patients to retrieve, manage, and share their electronic health records. Through a licensing agreement with Health Wizz, the company is building a branded mobile app and a HIPAA compliant backend and web portal backed with blockchain technology to ensure security and integrity.

The consumer-facing platform will also enable Ehave to recruit participants with screening surveys and provide researchers with access to complete medical histories. Smart contracts on the Ethereum blockchain make it easy to reward participants with redeemable “OMP” tokens for each milestone to encourage participation.

Adding Ancillary Services

Ehave augmented its digital presence with services in recent quarters. For instance, in December, the company bought San Diego-based CureDash, which provides home delivery services for patients that have been prescribed ketamine under the brand KetaDASH. The move helps the company move further up the value chain to reach patients.

In conjunction with the purchase, the company is designing an innovative and intuitive dashboard for KetaDash where clients and nurses can get detailed insights into how ketamine therapies work. Patients will be able to create a profile, check the availability of nurses, schedule appointments, and easily access their data.

A Compelling Business Model

Ehave’s digital therapeutics platform paves the way for an attractive long-term business model. With the launch of its consumer-facing app, the company aims to create a marketplace for participants to sign up for research programs in exchange for compensation. These research programs could yield valuable clinical data.

The company’s proprietary platform creates a barrier to entry for competitors in the space, while the data generated from the platform could be monetized through subscriptions or licensing agreements. Both of these business models create the opportunity for high-margin recurring revenue for the company’s shareholder base.

The company has built an exceptional management team and advisory board to ensure that it reaches these goals. For example, in June, Dr. Jeffrey D. Kamlet, MD, a pain medicine specialist in Miami Beach, FL, specializing in ketamine treatments, joined the company as Chief Medical Officer, adding to the team’s deep industry expertise.

Click here to receive an investor presentation and corporate updates

Looking Ahead

Ehave Inc. (OTC Pink: EHVVF) provides investors with a unique opportunity to participate in the upside of psychedelics. With clinic and client-facing applications, the company is building an ecosystem that is already validating psychedelic therapies through research agreements and asset purchases.

For more information, visit the company’s website or download their investor presentation.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading